Literature DB >> 27525856

Association between the WRAP53 gene rs2287499 C>G polymorphism and cancer risk: A meta-analysis.

H Y Cao1, S Wang1, Z Y Zhang1, J Y Lou2.   

Abstract

The TP53 5'-untranslated region flanking the gene WRAP53 (also known as WDR79 and TCAB1) has been hypothesized to be associated with cancer risk due to its critical function in regulating p53 levels. In this review, we analyzed the association between the WRAP53 gene rs2287499 C>G polymorphism and risk of cancer using five case-control studies, comprising seven datasets. All analyses were performed using RevMan software. In the overall analysis, no significant association between rs2287499 and risk of cancer was found. We then conducted subgroup tests, stratifying the data by cancer type, ethnicity, sample source, and quality score. Only the brain and breast cancer subgroups returned significant results, but with conflicting implications. Our concerns regarding this are discussed in detail. In conclusion, the rs2287499 polymorphism may be associated with risk of cancer. Further studies taking into consideration a broader range of cancer types and different ethnicities are warranted.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27525856     DOI: 10.4238/gmr.15037976

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  3 in total

1.  Nuclear WRAP53 promotes neuronal survival and functional recovery after stroke.

Authors:  Irene Sánchez-Morán; Cristina Rodríguez; Rebeca Lapresa; Jesús Agulla; Tomás Sobrino; José Castillo; Juan P Bolaños; Angeles Almeida
Journal:  Sci Adv       Date:  2020-10-07       Impact factor: 14.136

2.  ncRNA-disease association prediction based on sequence information and tripartite network.

Authors:  Takuya Mori; Hayliang Ngouv; Morihiro Hayashida; Tatsuya Akutsu; Jose C Nacher
Journal:  BMC Syst Biol       Date:  2018-04-11

3.  Haplotype and linkage disequilibrium of TP53-WRAP53 locus in Iranian-Azeri women with breast cancer.

Authors:  Nasser Pouladi; Sepehr Abdolahi; Davoud Farajzadeh; Mohammad Ali Hosseinpour Feizi
Journal:  PLoS One       Date:  2019-08-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.